GTS Securities’s Teva Pharmaceuticals TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-116,900
Closed -$2.11M 3815
2024
Q3
$2.11M Sell
116,900
-18,700
-14% -$327K ﹤0.01% 1543
2024
Q2
$2.2M Sell
135,600
-248,900
-65% -$3.83M ﹤0.01% 1426
2024
Q1
$5.43M Buy
384,500
+41,300
+12% +$521K 0.01% 811
2023
Q4
$3.58M Buy
343,200
+107,900
+46% +$1.01M 0.01% 1231
2023
Q3
$2.4M Buy
+235,300
New +$2.19M ﹤0.01% 1399

Other funds holding TEVA

GTS Securities's TEVA Position: Q1 2026 in Review

GTS Securities opened a new position in Teva Pharmaceuticals (TEVA) in Q1 2026: 46,218 shares worth $1.39M. The stake represents 0.05% of the portfolio and ranks #281 among its holdings. This is a return to the name: GTS Securities previously reported a position in TEVA as recently as Q3 2025.

GTS Securities first reported a position in TEVA in Q2 2023 and has held it in 10 quarters since. The position peaked at $14.5M in Q1 2024. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • GTS Securities held 46,218 shares of Teva Pharmaceuticals worth $1.39M as of Q1 2026.
  • Teva Pharmaceuticals was a new GTS Securities position in Q1 2026.
  • Teva Pharmaceuticals made up 0.05% of GTS Securities's portfolio in Q1 2026, its #281 holding.
  • GTS Securities first reported a position in Teva Pharmaceuticals in Q2 2023 and has held it in 10 quarters since.
  • GTS Securities's Teva Pharmaceuticals position peaked at $14.5M in Q1 2024.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.